Baloxavir
To view the entire topic, please log in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
- Treatment of uncomplicated influenza, ages ≥ 12 years with symptoms < 48 hours.
- Limitations of use: Consideration should be given to susceptibility patterns for circulating influenza virus strains when deciding whether to use baloxavir because viruses’ changing over time, virus type or subtype, the emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs.
NON-FDA APPROVED USES
- Treatment of influenza in individuals at high risk for influenza-related complications
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
- Treatment of uncomplicated influenza, ages ≥ 12 years with symptoms < 48 hours.
- Limitations of use: Consideration should be given to susceptibility patterns for circulating influenza virus strains when deciding whether to use baloxavir because viruses’ changing over time, virus type or subtype, the emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs.
NON-FDA APPROVED USES
- Treatment of influenza in individuals at high risk for influenza-related complications
There's more to see -- the rest of this entry is available only to subscribers.